Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Recommendation of “Moderate Buy” by Analysts

Vyome Holdings, Inc. (NASDAQ:HIND) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.25.

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Chardan Capital began coverage on Vyome in a report on Thursday, September 3rd. They issued a “buy” rating and a $3.50 target price on the stock.

Vyome Price Performance

Shares of HIND opened at $2.06 on Thursday. Vyome has a 1 year low of $1.75 and a 1 year high of $9.56. The company has a 50 day simple moving average of $2.18 and a two-hundred day simple moving average of $2.26. The firm has a market cap of $14.46 million, a P/E ratio of -0.61 and a beta of 1.50.

Vyome (NASDAQ:HIND) last released its earnings results on Wednesday, August 12th. The company reported ($0.10) EPS for the quarter. The company had revenue of $0.27 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.

Institutional Trading of Vyome

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC acquired a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent reporting period. 22.06% of the stock is owned by institutional investors.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.